Not Signed In - Nastech Initiates Clinical Development Of Rapid Acting Insulin Nasal Spray For Diabetes
Wed, 20 Sep 2006 07:00 AM EST
... Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today the initiation of a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability and glucose response of Nastech's proprietary, rapid acting intranasal insulin formulation. [click link for full article] ...
Related Topics
- Insulin
- Insulin Resistance
- Clinical Trials
- Calcitonin Salmon Nasal Spray
- Mometasone Nasal Spray
- Sumatriptan Nasal Spray
- Zolmitriptan Nasal Spray
- Nicotine nasal spray
- Azelastine Nasal Spray
- Child Development
- Triamcinolone Nasal Inhalation
- Fetal Development
- Gestational Diabetes
- Fluticasone Nasal Inhalation
- Beclomethasone Nasal Inhalation
- Teen Development
- Phenylephrine Nasal
- Insulin glargine
- Cromolyn Nasal Spray
- Budesonide Nasal Inhaler
email this page
print this page
bookmark this page
feedback on this page
